Amedisys has downside risk, says Credit Suisse

theflyonthewall.com

Credit Suisse said recent Amedisys strength is difficult to justify given likely persistent operating pressures and turnaround efforts that could take years. Shares are Underperform rated with a $10 price target.

Rates

View Comments (0)